Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 4/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24241468 | 0.74 | CTSA (0.42) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL14784182 | 0.72 | KMT2A (0.45) | PLAUKMT2AMEN1LMNAMAPT | |
| SCHEMBL31518081 | 0.70 | ALDH1A1 (0.46) | PDK1PDK2PDK3PDK4PTPN1 | |
| SCHEMBL14784385 | 0.70 | ALDH1A1 (0.46) | PDK1PDK2PDK3PDK4PTPN1 | |
| SCHEMBL31518207 | 0.67 | KMT2A (0.52) | PDK1PDK2PDK3PDK4PTPN1 | |
| SCHEMBL10932040 | 0.67 | ALDH1A1 (0.47) | PDK1PDK2PDK3PDK4PTPN1 | |
| SCHEMBL14784216 | 0.67 | KMT2A (0.52) | PDK1PDK2PDK3PDK4PTPN1 | |
| SCHEMBL28088014 | 0.67 | CES1 (0.42) | PLAUMAPT | |
| SCHEMBL14784661 | 0.67 | P2RX7 (0.40) | CFTRMAPT | |
| SCHEMBL2372434 | 0.65 | CFTR (0.69) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755967-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9034879-B2 | Heterocyclic compounds for the treatment of CF | NOVARTIS AG (CH) | 2015-05-19 | — | — | US | disclosed |
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2755967-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038386-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228376-A1 | Heterocyclic Compounds for the Treatment of CF | CFTR, OPRD1, OPRK1 | PDK1 1062/4885PDK2 2235/4885PDK3 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.